ADVAXIS WKN: A2PGJ3 ISIN: US0076243072 Kürzel: FAD2 Forum: Aktien Thema: Hauptdiskussion

PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock. The record date for such dividend distribution is October 12, 2020. The rights plan expires, without any further action being required to be taken by the Company’s Board of Directors, on September 28, 2021.

Was war den da letzte Woche los ? Spike des Jahres?

Was eine verarsche hier! Hätt besser gestern den Mist verkauft....

Es ist sogar schlechter als gestern. Wahnsinn. Viele sind am vermeintlichen Boden rein und ratzfatz mit 40-50%. Die Bagholder haben nen ganz anderen EK

Phase 1 halt. Aber schon krass abverkauft. Da wollten viele raus.

Wie es fällt 😂

Nicht nur als Investor erfreulich 🙏

PRINCETON, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc.(ADXS) , a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the U.S. Food and Drug Administration (FDA) has cleared a new Investigational New Drug (IND) application for the initiation of an Investigator Sponsored Phase 1 clinical study of ADXS-504, the Company’s off-the-shelf neoantigen ADXS-HOT candidate for prostate cancer. This new IND is in addition to the Advaxis(ADXS) sponsored IND, previously announced in January 2020. Advaxis(ADXS) intends to first advance the clinical evaluation of ADXS-504 through an Investigator Sponsored Phase 1 study in prostate cancer patients with biochemical recurrence which remains on-track for initiation in the fourth quarter this year.

Advaxis gibt FDA-Zulassung des neuen IND für ADXS-504 zur Behandlung von Prostatakrebs bekannt https://www.advaxis.com/news-releases/news-release-details/advaxis-announces-fda-clearance-new-ind-adxs-504-treatment

???

Sehe da noch nicht den Grund, warum wir jetzt die compliance erreichen sollten

Danke für die Infos Warren.

503 läuft gut, 504 wird initialisiert. PSA kein Wort. Cash bis 07/2021

Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors Enrolling in Phase 1/2 Study efficacy expansion of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two of three evaluable patients from Part B combination arm with KEYTRUDA® Enrolling in Part C for first-line regimen with KEYTRUDA® in NSCLC patients with PD-L1 expression ≥ 1% and patients who are unfit for standard of care combination therapy with KEYTRUDA® and platinum-based chemotherapy

Research and development expenses for the third quarter of fiscal year 2020 were $3.5 million, compared with $7.1 million for the third quarter of fiscal year 2019. The decrease is largely attributable to the winding down of the Phase 3 AIM2CERV and Phase 1 ADXS-NEO studies as announced in June 2019 and October 2019, respectively. General and administrative expenses for the three months ended July 31, 2020 were approximately $2.4 million compared to $3.1 million in the same three-month period in 2019. The decrease in expenses is mainly attributable to lower legal fees and business development costs. As of July 31, 2020, the Company had approximately $23.8 million in cash and cash equivalents. The Company believes this is sufficient capital to fund its obligations, as they become due, in the ordinary course of business until July 2021

Weh tut mir gerade Shell und eine China Aktie, steckt man nicht immer hinter.